Gossypium herbaceam extracts attenuate ibotenic acid-induced excitotoxicity in rat hippocampus.
Excitotoxicity is one of the most extensively studied processes of neuronal death and plays an important role in Alzheimer's disease. In the present study, the protective effects of Gossypium herbaceam extracts (GHE) on learning and memory impairment induced by excitatory neurotoxin ibotenic acid were examined in vivo using Morris water maze. Furthermore, neuroprotective effects of GHE were investigated with methods of immunohistochemistry and biochemistry. Our data showed that oral administration with GHE at the doses of 35, 70 and 140 mg/kg exerted an improved effect on the learning and memory impairment in rats induced by intracerebral injection of ibotenic acid. To confirm the precise mechanism of memory improvement by presence of GHE, we further investigated the potential protection on the hippocampus. Our findings suggest that GHE afforded a beneficial inhibition on pro-apoptosis proteins expression following ibotenic acid. Additionally, calcium pump activity and calbindin-D28k expression were dramatically increased after GHE treatment, implicating that the modulation of calcium homeostasis could be involved in the mechanism underlying neuroprotection of GHE against ibotenic acid-induced excitotoxicity. These data suggested that GHE could be a potential agent for preventing or retarding the development or progression of Alzheimer's disease.
Ji
Chao
C
School of Basic Medicine, Peking Union Medical College & Institute of Basic Medical Science, Chinese Academy of Medical Sciences, Beijing, China.
Li
Qing
Q
Aisa
HajiAkber
H
Yang
Nan
N
Dong
Yi-Long
YL
Liu
Yan-Yong
YY
Wang
Tao
T
Hao
Qiang
Q
Zhu
Hai-Bo
HB
Zuo
Ping-Ping
PP
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D064092:Calbindin 1; D064026:Calbindins; D000252:Calcium-Transporting ATPases / Q000378:metabolism; D053148:Caspase 3 / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004924:Escape Reaction / Q000187:drug effects; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity; D003368:Gossypium / Q000737:chemistry*; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D007051:Ibotenic Acid / Q000633:toxicity; D007276:Injections, Intraventricular / Q000379:methods; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D008517:Phytotherapy / Q000379:methods*; D028321:Plant Preparations / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D064030:S100 Calcium Binding Protein G / Q000378:metabolism; D013997:Time Factors; D051028:bcl-2-Associated X Protein / Q000378:metabolism
C576500:Calb1 protein, rat; D064092:Calbindin 1; D064026:Calbindins; D018690:Excitatory Amino Acid Agonists; D028321:Plant Preparations; D019253:Proto-Oncogene Proteins c-bcl-2; D064030:S100 Calcium Binding Protein G; D051028:bcl-2-Associated X Protein; D007051:Ibotenic Acid; D053148:Caspase 3; D000252:Calcium-Transporting ATPases